Filing Details

Accession Number:
0001127602-12-032078
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-11-26 20:45:22
Reporting Period:
2012-11-26
Filing Date:
2012-11-26
Accepted Time:
2012-11-26 20:45:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1184227 S Gilbert Omenn One Amgen Center Drive
Thousand Oaks CA 91320-1799
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-11-26 16,000 $50.78 192,783 No 4 M Direct
Common Stock Acquisiton 2012-11-26 5,000 $74.89 197,783 No 4 M Direct
Common Stock Acquisiton 2012-11-26 5,000 $62.55 202,783 No 4 M Direct
Common Stock Disposition 2012-11-26 26,000 $87.11 176,783 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Nqso (Right to Buy) Disposition 2012-11-26 16,000 $0.00 16,000 $50.78
Common Stock Nqso (Right to Buy) Disposition 2012-11-26 5,000 $0.00 5,000 $74.89
Common Stock Nqso (Right to Buy) Disposition 2012-11-26 5,000 $0.00 5,000 $62.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2003-01-27 2013-01-27 No 4 M Direct
0 2006-03-15 2013-03-15 No 4 M Direct
0 2007-04-26 2014-04-26 No 4 M Direct
Footnotes
  1. The price reported is an average price. The prices ranged from $87.095 to $87.13 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
  2. These shares include 108 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.